Back to results
US 12,761,224 B2Granted
AGR2Xcd3 bispecific engager for the treatment of cancer
AssigneeMUSC Foundation for Research Development
InventorsNathan G. Dolloff, Reeder M. Robinson
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to AGR2 and cancer cells that express or overexpress AGR2, and methods for use thereof.
Claims25
A method of detecting an AGR2-expression or overexpressing cancer in a subject comprising:
- (a) contacting a sample from said subject with an antibody, single chain antibody or antibody fragment comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9-11, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18-20, respectively, or
- comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9, 12 and 13, respectively, and light chain CDRl-3 comprising SEO ID NOS:
- 18, 21 and 22, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 14 and 15, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 23 and 24, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 16 and 17, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 25 and 26, respectively;
- and
- (b) detecting an AGR2-expression or overexpressing cancer cells in said sample by binding of said antibody, single chain antibody or antibody fragment to a cancer cell in said sample.
11 more elements
A method of treating a subject having an AGR2-expressing or overexpressing cancer comprising delivering to said subject an antibody, single chain antibody or antibody fragment comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9-11, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18-20, respectively, or
- comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9, 12 and 13, respectively, and light chain CDRl-3 comprising SEO ID NOS:
- 18, 21 and 22, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 14 and 15, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 23 and 24, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 16 and 17, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 25 and 26, respectively;
- and
- (b) detecting an AGR2-expression or overexpressing cancer cells in said sample by binding of said antibody, single chain antibody or antibody fragment to a cancer cell in said sample.
10 more elements
An antibody, single chain antibody or antibody fragment,
- comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9-11, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18-20, respectively, or
- comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9, 12 and 13, respectively, and light chain CDRl-3 comprising SEO ID NOS:
- 18, 21 and 22, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 14 and 15, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 23 and 24, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 16 and 17, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 25 and 26, respectively.
9 more elements
A hybridoma or engineered cell encoding an antibody, single chain antibody or antibody fragment wherein the antibody, single chain antibody or antibody fragment comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9-11, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18-20, respectively, or
- comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9, 12 and 13, respectively, and light chain CDRl-3 comprising SEO ID NOS:
- 18, 21 and 22, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 14 and 15, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 23 and 24, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 16 and 17, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 25 and 26, respectively;
- and
- (b) detecting an AGR2-expression or overexpressing cancer cells in said sample by binding of said antibody, single chain antibody or antibody fragment to a cancer cell in said sample.
10 more elements
A chimeric antigen receptor comprising:
- (i) an ectodomain comprising single chain antibody variable region comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9-11, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18-20, respectively, or
- comprising heavy chain CDRl-3 comprising SEQ ID NOS:
- 9, 12 and 13, respectively, and light chain CDRl-3 comprising SEO ID NOS:
- 18, 21 and 22, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 14 and 15, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 23 and 24, respectively,
- or comprising heavy chain CDRl-3 SEQ ID NOS:
- 9, 16 and 17, respectively, and light chain CDRl-3 comprising SEQ ID NOS:
- 18, 25 and 26, respectively;
- and with a flexible hinge attached at the C-terminus of said single chain antibody variable region;
- (ii) a transmembrane domain;
- and
- (iii) an endodomain, wherein said endodomain comprises a signal transduction function when said single-chain antibody variable region is engaged with MUC1.
13 more elements
Dependencies are inferred from the claim text.